{"id":7585,"date":"2025-04-10T09:06:33","date_gmt":"2025-04-10T09:06:33","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7585"},"modified":"2025-04-10T09:06:33","modified_gmt":"2025-04-10T09:06:33","slug":"research-group-on-human-translational-genomics","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/que-hacemos\/areas\/metabolismo-y-dano-organico\/research-group-on-human-translational-genomics\/","title":{"rendered":"Research Group on Human Translational Genomics"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container fusion-parallax-none nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #ededed;background-image: url(&quot;https:\/\/www.incliva.es\/wp-content\/uploads\/2021\/01\/fondo.jpg&quot;);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_3_4 3_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-1\" style=\"transform:translate3d(0,0,0);\"><h3>Research Group on Human Translational Genomics<\/h3>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-2\" style=\"transform:translate3d(0,0,0);\"><h5><span style=\"color: #3D44AC;\">Metabolism and Organic Damage Area<\/span><\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-3\" style=\"transform:translate3d(0,0,0);\"><div>\n<!--objetivosgrupo--><br \/>\nMedium-term scientific research aims are to investigate mechanisms of pathogenesis and candidate therapies in Myotonic Dystrophy, Spinal Muscular Atrophy, LGMDD2, and cancer-induced cachexia; to optimize oligonucleotide drug delivery methods; and to screen and repurpose drugs in additional biomedical models in Drosophila<br \/>\n<!--objetivosgrupo fin-->\n<\/div>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-0{width:75% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-0 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 2.56%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 2.56%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-0{width:75% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 2.56%;margin-left : 2.56%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-0{width:100% !important;}.fusion-builder-column-0 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;background-color:#ffffff;border-width: 0 0 0 2px;border-color:#9da0d2;border-style:solid;padding: 4% 4% 4% 4%;\">\n<div ><span class=\" fusion-imageframe imageframe-none imageframe-1 hover-type-none\" style=\"border-radius:5px;\"><img src=\"\/wp-content\/uploads\/2025\/02\/Ruben-Artero.jpg\" class=\"img-responsive\"\/><\/span><\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-top:10px;margin-bottom:10px;width:100%;\"><\/div>\n<div class=\"fusion-text fusion-text-4\" style=\"transform:translate3d(0,0,0);\"><h5 class=\"titulo-coordinador\" style=\"text-align: center;\">Coordinator<\/h5>\n<div class=\"nombre-coordinador\" style=\"text-align: center;\">Dr. Rub\u00e9n D Artero Allepuz<br \/>\n<a class=\"link extra_email\" href=\"mailto:ruben.artero@uv.es\">ruben.artero@uv.es<\/a><\/p>\n<a class=\"fb-icon-element-1 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:32px;margin-right:16px;\" href=\"\/en\/ruben-d-artero-allepuz\/\" aria-label=\"Link to \/en\/ruben-d-artero-allepuz\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-1{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-1:hover { color: #9da0d2;}<\/style><\/div>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-1{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-1 > .fusion-column-wrapper {padding-top : 4% !important;padding-right : 4% !important;margin-right : 7.68%;padding-bottom : 4% !important;padding-left : 4% !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-1{width:25% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-1{width:100% !important;order : 0;}.fusion-builder-column-1 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-fullwidth.fusion-builder-row-1 { overflow:visible; }.fusion-body .fusion-flex-container.fusion-builder-row-1{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-5\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">RESEARCHERS<\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-2{width:100% !important;margin-top : 10px;margin-bottom : 20px;}.fusion-builder-column-2 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-2{width:100% !important;order : 0;}.fusion-builder-column-2 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-6\" style=\"transform:translate3d(0,0,0);\"><h5>Leading, R4<\/h5>\n<p>Rub\u00e9n D Artero Allepuz &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-2 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/ruben-d-artero-allepuz\/\" aria-label=\"Link to \/en\/ruben-d-artero-allepuz\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-2{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-2:hover { color: #9da0d2;}<\/style><\/br>Manuel P\u00e9rez Alonso<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-3{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-3 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-3{width:25% !important;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-3{width:100% !important;}.fusion-builder-column-3 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-7\" style=\"transform:translate3d(0,0,0);\"><h5>Established, R3<\/h5>\n<p>Arturo L\u00f3pez Castel<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-4{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-4 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-4{width:25% !important;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-4{width:100% !important;}.fusion-builder-column-4 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-8\" style=\"transform:translate3d(0,0,0);\"><h5>Recognised\/Emerging, R2<\/h5>\n<p>Raquel Atienzar Aroca<\/br>Mar\u00eda Sabater Arcis<\/br>Javier Poyatos Garc\u00eda<\/br>Ariadna Bargiela Sch\u00f6nbrunn &nbsp;&nbsp;&nbsp;<a class=\"fb-icon-element-3 fb-icon-element fontawesome-icon fa-address-card fas circle-no fusion-text-flow fusion-link\" style=\"font-size:21px;margin-right:10.5px;\" href=\"\/en\/ariadna-bargiela-sch\u00f6nbrunn\/\" aria-label=\"Link to \/en\/ariadna-bargiela-sch\u00f6nbrunn\/\" target=\"_self\">\n<\/a><style>a.fb-icon-element.fontawesome-icon.fb-icon-element-3{ color: #3D44AC;}a.fb-icon-element.fontawesome-icon.fb-icon-element-3:hover { color: #9da0d2;}<\/style><\/br>Raquel P\u00e9rez G\u00f3mez<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-5{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-5 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-5{width:25% !important;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-5{width:100% !important;}.fusion-builder-column-5 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-9\" style=\"transform:translate3d(0,0,0);\"><h5>First Stage, R1<\/h5>\n<p>Paola Jazmin Yanez Atiencia <\/br>Natalia Mariel Riedel Bistoco<\/br>Irene Gonz\u00e1lez Mart\u00ednez<\/br>Anna Colom Rodrigo<\/br>Alicia Novella Estell\u00e9s<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-6{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-6 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-6{width:25% !important;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-6{width:100% !important;}.fusion-builder-column-6 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-2{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: rgba(255,255,255,0);background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<div class=\"fusion-text fusion-text-10\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: center;\">STAFF<\/h5>\n<\/div>\n<div class=\"fusion-separator fusion-full-width-sep\" style=\"align-self: center;margin-left: auto;margin-right: auto;margin-bottom:10px;width:100%;\"><div class=\"fusion-separator-border sep-single sep-solid\" style=\"border-color:#9da0d2;border-top-width:1px;\"><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-7{width:100% !important;margin-top : 10px;margin-bottom : 20px;}.fusion-builder-column-7 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-7{width:100% !important;order : 0;}.fusion-builder-column-7 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-11\" style=\"transform:translate3d(0,0,0);\"><h5>Collaborating Researchers<\/h5>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-8{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-8 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-8{width:25% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-8{width:100% !important;}.fusion-builder-column-8 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-12\" style=\"transform:translate3d(0,0,0);\"><h5>Nurse<\/h5>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-9{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-9 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-9{width:25% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-9{width:100% !important;}.fusion-builder-column-9 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-10 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-13\" style=\"transform:translate3d(0,0,0);\"><h5>Technicians<\/h5>\n<p>Iv\u00e1n Gimeno Mart\u00ednez<\/br>Anna Ballestar Carri\u00f3n<\/br><\/p>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-10{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-10 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-10{width:25% !important;}.fusion-builder-column-10 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-10{width:100% !important;}.fusion-builder-column-10 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-11 fusion_builder_column_1_4 1_4 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-14\" style=\"transform:translate3d(0,0,0);\"><h5>Administrative assistant<\/h5>\n<\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-11{width:25% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-11 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 7.68%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 7.68%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-11{width:25% !important;}.fusion-builder-column-11 > .fusion-column-wrapper {margin-right : 7.68%;margin-left : 7.68%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-11{width:100% !important;}.fusion-builder-column-11 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-3{ padding-top : 0px;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-12 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-15\" style=\"transform:translate3d(0,0,0);\"><h5>Publications<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-1 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-1 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-1 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-1 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-1 .nav,.fusion-tabs.fusion-tabs-1 .nav-tabs,.fusion-tabs.fusion-tabs-1 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-abb7add670b8cb72df2\" aria-selected=\"true\" id=\"fusion-tab-2023\" href=\"#tab-abb7add670b8cb72df2\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-2fb6b52f8f28c07bb59\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2022\" href=\"#tab-2fb6b52f8f28c07bb59\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-8876297ed37b0038648\" aria-selected=\"false\" tabindex=\"-1\" id=\"fusion-tab-2021\" href=\"#tab-8876297ed37b0038648\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-abb7add670b8cb72df2\" aria-selected=\"true\" id=\"mobile-fusion-tab-2023\" href=\"#tab-abb7add670b8cb72df2\"><h4 class=\"fusion-tab-heading\">2023<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2023\" id=\"tab-abb7add670b8cb72df2\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nBlockmiR AONs as site-specific therapeutic mbnl modulation in myotonic dystrophy 2D and 3D muscle cells and HSALR mice. Overby S, Cerro-Herreros E, Espinosa-Espinosa J, Gonzalez-Martinez I, Moreno N, Fernandez-Costa J, Balaguer-Trias J, Ramon-Azcon J, Perez-Alonso M, Moller T, Llamusi B, Artero R. Pharmaceutics. 2023 Mar 31;15(4):1118. doi: <a href='https:\/\/doi.org\/10.3390\/pharmaceutics15041118' target='_blank'>10.3390\/pharmaceutics15041118<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37111604' target='_blank'>37111604<\/a><\/p>\n<p>CRISPR-Cas9 editing of a TNPO3 mutation in a muscle cell model of limb-girdle muscular dystrophy type D2. Poyatos Garcia J, Blazquez Bernal A, Selva Gimenez M, Bargiela A, Espinosa Espinosa J, Vazquez Manrique RP, Bigot A, Artero R, Vilchez JJ. Molecular Therapy. Nucleic Acids. 2023 Jan 11;31:324-338. doi: <a href='https:\/\/doi.org\/10.1016\/j.omtn.2023.01.004' target='_blank'>10.1016\/j.omtn.2023.01.004<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36789274' target='_blank'>36789274<\/a><\/p>\n<p>Development of potent tripodal G-quadruplex DNA binders and their efficient delivery to cancer cells by aptamer functionalised liposomes. Pont I, Galiana-Rosello C, Sabater-Arcis M, Bargiela A, Frias J, Albelda M, Gonzalez-Garcia J, Garcia-Espana E. Organic &#038; Biomolecular Chemistry. 2023 Feb 1;21(5):1000-1007. doi: <a href='https:\/\/doi.org\/10.1039\/d2ob01911f' target='_blank'>10.1039\/d2ob01911f<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36541358' target='_blank'>36541358<\/a><\/p>\n<p>Msi2 enhances muscle dysfunction in a myotonic dystrophy type 1 mouse model. Sabater-Arcis M, Moreno N, Sevilla T, Perez Alonso M, Bargiela A, Artero R. Biomedical Journal. 2023 Oct 3:100667. doi: <a href='https:\/\/doi.org\/10.1016\/j.bj.2023.100667' target='_blank'>10.1016\/j.bj.2023.100667<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37797921' target='_blank'>37797921<\/a><\/p>\n<p>Natural compound boldine lessens myotonic dystrophy type 1 phenotypes in DM1 drosophila models, patient-derived cell lines, and HSALR mice. Alvarez-Abril M, Garcia-Alcover I, Colonques-Bellmunt J, Garijo R, Perez-Alonso M, Artero R, Lopez-Castel A. International Journal of Molecular Sciences. 2023 Jun 6;24(12):9820. doi: <a href='https:\/\/doi.org\/10.3390\/ijms24129820' target='_blank'>10.3390\/ijms24129820<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37372969' target='_blank'>37372969<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7585-1 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7585-1 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7585-1.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7585-1 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7585-1 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7585-1 .panel-title a:hover, #accordion-7585-1 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7585-1 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7585-1 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7585-1\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"107d4c6384a62cebb\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7585-1\" data-target=\"#107d4c6384a62cebb\" href=\"#107d4c6384a62cebb\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2023<\/span><\/a><\/h4><\/div><div id=\"107d4c6384a62cebb\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nNeuroprotective properties of queen bee acid by autophagy induction. Mart\u00ednez-Chac\u00f3n G, Paredes-Barquero M, Yakhine-Diop SMS, Uribe-Carretero E, Bargiela A, Sabater-Arcis M, Morales-Garc\u00eda J, Alarc\u00f3n-Gil J, Alegre-Cort\u00e9s E, Canales-Cort\u00e9s S, Rodr\u00edguez-Arribas M, Camello PJ, Pedro JMB, Perez-Castillo A, Artero R, Gonzalez-Polo RA, Fuentes JM, Niso-Santano M. Cell Biology and Toxicology. 2023 Jun;39(3):751-770. doi: <a href='https:\/\/doi.org\/10.1007\/s10565-021-09625-w' target='_blank'>10.1007\/s10565-021-09625-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34448959' target='_blank'>34448959<\/a><\/p>\n<p>Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression. Gonzalez-Martinez I, Cerro-Herreros E, Moreno N, Garcia-Rey A, Espinosa-Espinosa J, Carrascosa-Saez M, Piqueras-Losilla D, Arzumanov A, Seoane-Miraz D, Jad Y, Raz R, Wood M, Varela M, Llamusi B, Artero R. Molecular Therapy. Nucleic Acids. 2023 Sep 5:34:102024. doi: <a href='https:\/\/doi.org\/10.1016\/j.omtn.2023.09.001' target='_blank'>10.1016\/j.omtn.2023.09.001<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/37744174' target='_blank'>37744174<\/a><\/p>\n<p>Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice. Bargiela A, Ten-Esteve A, Marti-Bonmati L, Sevilla T, Perez Alonso M, Artero R. Scientific Reports. 2023 Jan 10;13(1):503. doi: <a href='https:\/\/doi.org\/10.1038\/s41598-023-27661-w' target='_blank'>10.1038\/s41598-023-27661-w<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36627397' target='_blank'>36627397<\/a><\/p>\n<p>The myotonic dystrophy type 1 drug development pipeline: 2022 edition. Pascual-Gilabert M, Artero R, Lopez-Castel A. Drug Discovery Today. 2023 Jan 9;28(3):103489. doi: <a href='https:\/\/doi.org\/10.1016\/j.drudis.2023.103489' target='_blank'>10.1016\/j.drudis.2023.103489<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36634841' target='_blank'>36634841<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-2fb6b52f8f28c07bb59\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2022\" href=\"#tab-2fb6b52f8f28c07bb59\"><h4 class=\"fusion-tab-heading\">2022<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2022\" id=\"tab-2fb6b52f8f28c07bb59\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nDeciphering the complex molecular pathogenesis of myotonic dystrophy type 1 through omics studies. Espinosa-Espinosa J, Gonzalez-Barriga A, Lopez-Castel A, Artero R. International Journal of Molecular Sciences. 2022 Jan 27;23(3):1441. doi: <a href='https:\/\/doi.org\/10.3390\/ijms23031441' target='_blank'>10.3390\/ijms23031441<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35163365' target='_blank'>35163365<\/a><\/p>\n<p>Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model. Januel C, Menduti G, Mamchaoui K, Martinat C, Artero R, Konieczny P, Boido M. Cellular and Molecular Life Sciences. 2022 Jul 22;79(8):441. doi: <a href='https:\/\/doi.org\/10.1007\/s00018-022-04450-8' target='_blank'>10.1007\/s00018-022-04450-8<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35864358' target='_blank'>35864358<\/a><\/p>\n<p>Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model. Overby SJ, Cerro Herreros E, Gonzalez Martinez I, Varela MA, Seoane Miraz D, Jad Y, Raz R, Moller T, Perez Alonso M, Wood MJ, Llamusi B, Artero R. Molecular Therapy. Nucleic Acids. 2022 Feb 10;27:1146-1155. doi: <a href='https:\/\/doi.org\/10.1016\/j.omtn.2022.02.003' target='_blank'>10.1016\/j.omtn.2022.02.003<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/35282418' target='_blank'>35282418<\/a><\/p>\n<p>Transgenic overexpression of myocilin leads to variable ocular anterior segment and retinal alterations associated with extracellular matrix abnormalities in adult zebrafish. Atienzar-Aroca R, Ferre-Fernandez J, Tevar A, Bonet-Fernandez J, Cabanero M, Ruiz-Pastor M, Cuenca N, Aroca-Aguilar J, Escribano J. International Journal of Molecular Sciences. 2022 Sep 1;23(17):9989. doi: <a href='https:\/\/doi.org\/10.3390\/ijms23179989' target='_blank'>10.3390\/ijms23179989<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/36077382' target='_blank'>36077382<\/a><\/p>\n<\/div>\n<\/div><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-8876297ed37b0038648\" aria-selected=\"false\" tabindex=\"-1\" id=\"mobile-fusion-tab-2021\" href=\"#tab-8876297ed37b0038648\"><h4 class=\"fusion-tab-heading\">2021<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-2021\" id=\"tab-8876297ed37b0038648\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\">\nBioengineered in vitro 3D model of myotonic dystrophy type 1 human skeletal muscle. Fernandez-Garibay X, Ortega MA, Cerro-Herreros E, Comelles J, Martinez E, Artero R, Fernandez-Costa JM, Ramon-Azcon J. Biofabrication. 2021 Apr 26;13(3). doi: <a href='https:\/\/doi.org\/10.1088\/1758-5090\/abf6ae' target='_blank'>10.1088\/1758-5090\/abf6ae<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33836519' target='_blank'>33836519<\/a><\/p>\n<p>Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease. Rapisarda A, Bargiela A, Llamusi B, Pont I, Estrada-Tejedor R, Garcia-Espana E, Artero R, Perez-Alonso M. Scientific Reports. 2021 Sep 30;11(1):19417. doi: <a href='https:\/\/doi.org\/10.1038\/s41598-021-98866-0' target='_blank'>10.1038\/s41598-021-98866-0<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34593893' target='_blank'>34593893<\/a><\/p>\n<p>Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). Klionsky D, Abdel-Aziz A, Abdelfatah S, et al. Autophagy. 2021 Jan;17(1):1-382. doi: <a href='https:\/\/doi.org\/10.1080\/15548627.2020.1797280' target='_blank'>10.1080\/15548627.2020.1797280<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33634751' target='_blank'>33634751<\/a><\/p>\n<p>Inhibition of autophagy rescues muscle atrophy in a LGMDD2 Drosophila model. Blazquez-Bernal A, Fernandez-Costa JM, Bargiela A, Artero R. FASEB Journal. 2021 Oct;35(10):e21914. doi: <a href='https:\/\/doi.org\/10.1096\/fj.202100539RR' target='_blank'>10.1096\/fj.202100539RR<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34547132' target='_blank'>34547132<\/a><\/p>\n<p>Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression. Sabater-Arcis M, Bargiela A, Moreno N, Poyatos-Garcia J, Vilchez J, Artero R. Molecular Therapy-Nucleic Acids. 2021 Aug 19;25:652-667. doi: <a href='https:\/\/doi.org\/10.1016\/j.omtn.2021.08.010' target='_blank'>10.1016\/j.omtn.2021.08.010<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34589284' target='_blank'>34589284<\/a><\/p>\n<style type=\"text\/css\">.fusion-accordian  #accordion-7585-2 .panel-title a .fa-fusion-box{ color: #ffffff;}.fusion-accordian  #accordion-7585-2 .panel-title a .fa-fusion-box:before{ font-size: 14px; width: 14px;}.fusion-accordian  #accordion-7585-2.fusion-toggle-icon-right .fusion-toggle-heading{ margin-right: 32px;}.fusion-accordian  #accordion-7585-2 .panel-title a{font-size:14px;}.fusion-accordian  #accordion-7585-2 .fa-fusion-box { background-color: #212934;border-color: #212934;}.fusion-accordian  #accordion-7585-2 .panel-title a:hover, #accordion-7585-2 .fusion-toggle-boxed-mode:hover .panel-title a { color: #3bafbf;}.fusion-accordian  #accordion-7585-2 .panel-title .active .fa-fusion-box,.fusion-accordian  #accordion-7585-2 .panel-title a:hover .fa-fusion-box { background-color: #3bafbf!important;border-color: #3bafbf!important;}<\/style><div class=\"accordian fusion-accordian\"><div class=\"panel-group fusion-toggle-icon-right\" id=\"accordion-7585-2\" role=\"tablist\">\n<div class=\"fusion-panel panel-default\" role=\"tabpanel\"><div class=\"panel-heading\"><h4 class=\"panel-title toggle\"><a aria-expanded=\"false\" aria-selected=\"false\" aria-controls=\"edbbfcb924c10217b\" role=\"tab\" data-toggle=\"collapse\" data-parent=\"#accordion-7585-2\" data-target=\"#edbbfcb924c10217b\" href=\"#edbbfcb924c10217b\"><span class=\"fusion-toggle-icon-wrapper\" aria-hidden=\"true\"><i class=\"fa-fusion-box\" aria-hidden=\"true\"><\/i><\/span><span class=\"fusion-toggle-heading\">More publications from 2021<\/span><\/a><\/h4><\/div><div id=\"edbbfcb924c10217b\" class=\"panel-collapse collapse \"><div class=\"panel-body toggle-content fusion-clearfix\">\nMyotonic dystrophy type 1 drug development: a pipeline toward the market. Pascual-Gilabert M, Lopez-Castel A, Artero R. Drug Discovery Today. 2021 Jul;26(7):1765-1772. doi: 10.1016\/j.drudis.2021.03.024. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/33798646' target='_blank'>33798646<\/a><\/p>\n<p>Practicing logical reasoning through drosophila segmentation gene mutants. Bargiela A, Artero R. Biochemistry and Molecular Biology Education. 2021 Sep;49(5):729-736. doi: <a href='https:\/\/doi.org\/10.1002\/bmb.21554' target='_blank'>10.1002\/bmb.21554<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34160891' target='_blank'>34160891<\/a><\/p>\n<p>Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy. Cerro-Herreros E, Gonzalez-Martinez I, Moreno N, Espinosa-Espinosa J, Fernandez-Costa JM, Colom-Rodrigo A, Overby SJ, Seoane-Miraz D, Poyatos-Garcia J, Vilchez JJ, Lopez de Munain A, Varela MA, Wood MJ, Perez-Alonso M, Llamusi B, Artero R. Molecular Therapy. Nucleic Acids. 2021 Jul 29;26:174-191. doi: <a href='https:\/\/doi.org\/10.1016\/j.omtn.2021.07.017' target='_blank'>10.1016\/j.omtn.2021.07.017<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34513303' target='_blank'>34513303<\/a><\/p>\n<p>Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage. Selma-Soriano E, Casillas-Serra C, Artero R, Llamusi B, Navarro J, Redon J. Scientific Reports. 2021 Jul 27;11(1):15287. doi: <a href='https:\/\/doi.org\/10.1038\/s41598-021-94710-7' target='_blank'>10.1038\/s41598-021-94710-7<\/a>. PMID: <a href='https:\/\/pubmed.ncbi.nlm.nih.gov\/34315987' target='_blank'>34315987<\/a><\/p>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-12{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-12 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-12{width:100% !important;}.fusion-builder-column-12 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-12{width:100% !important;}.fusion-builder-column-12 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-4{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #9da0d2;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-13 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-16\" style=\"transform:translate3d(0,0,0);\"><h5 style=\"text-align: left;\">Projects<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-2 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-2 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-2 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-2 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-2 .nav,.fusion-tabs.fusion-tabs-2 .nav-tabs,.fusion-tabs.fusion-tabs-2 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7062b35d4a9414ad36b\" aria-selected=\"true\" id=\"fusion-tab-projects\" href=\"#tab-7062b35d4a9414ad36b\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-7062b35d4a9414ad36b\" aria-selected=\"true\" id=\"mobile-fusion-tab-projects\" href=\"#tab-7062b35d4a9414ad36b\"><h4 class=\"fusion-tab-heading\">PROJECTS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-projects\" id=\"tab-7062b35d4a9414ad36b\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:left;\">\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>INVEST\/2022\/81<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Utilizaci\u00f3n de Drosophila melanogaster en el desarrollo de oligonucle\u00f3tidos antisentido como medicamentos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Arturo L\u00f3pez Castell<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>66.218 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>INVEST\/2022\/63<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Especializaci\u00f3n en fenotipado y caracterizaci\u00f3n molecular de modelos biom\u00e9dicos murinos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>44.812 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>DTS22\/00088<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Optimizaci\u00f3n de par\u00e1metros PK\/PD de una terapia farmacol\u00f3gica reutilizada para pacientes con AME<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211;<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>134200\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI21\/00311<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Caracterizaci\u00f3n de una nueva diana terap\u00e9utica en disfunci\u00f3n muscular en la distrofia miot\u00f3nica de tipo 1<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Manuel P\u00e9rez Alonso<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>141.570 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>DTS21\/00081<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo precl\u00ednico de gapmers contra una nueva diana terap\u00e9utica en Distrofia Miot\u00f3nica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Manuel P\u00e9rez Alonso<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>127.600 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PLEC2022-009367<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Nuevas herramientas en moscas y cultivos en 3D para el desarrollo de oligonucle\u00f3tidos terap\u00e9uticos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Arturo L\u00f3pez Castel<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>46.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>MRR\/PDC2022-133103-I00<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo precl\u00ednico de un f\u00e1rmaco Gapmer para tratar distrofia miot\u00f3nica y otras atrofias musculares<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2024<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>149.500 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PID2021-125978OB-C22<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Comprensi\u00f3n de la atrofia muscular inducida por TNPO3 mutante: modelos precl\u00ednicos y aproximaciones terap\u00e9uticas en LGMDD2<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2025<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>242.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>EIN2020-112137<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Del RNA t\u00f3xico a la medicina traslacional en Distrofia Miot\u00f3nica (para la captaci\u00f3n de recursos UE)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2022 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>15.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>INNVA1\/2021\/44<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Reposicionamiento de un f\u00e1rmaco para atrofia muscular espinal<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Agencia Valenciana de la Innovaci\u00f3n-AVI Generalitat Valenciana<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>487.727 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>GV\/2021\/014<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Caracterizaci\u00f3n de la contribuci\u00f3n de MSI2 a la atrofia muscular de DM1 utilizando nuevos modelos celulares y murinos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Ariadna Bargiela Sch\u00f6nbrunn<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>10.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>CI21-00135<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Valorization of the repurposing of two drug candidates for spinal muscular atrophy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Fundaci\u00f3n Bancaria La Caixa<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>100.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI-2021-008<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>miR-OA: Inhibidores de miRNAs como terapia en osteoartritis<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Universidad de Valencia &#8211; INCLIVA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz, Carmen Carda Batalla<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2021 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>19.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PROMETEO\/2020\/081<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Uso de moduladores de microRNAs como terapias experimentales en distrofia miot\u00f3nica de tipo 1<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Conselleria de Innovaci\u00f3n, Universidades, Ciencia y Sociedad Digital<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2020 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>193.051 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PRECIPITA-DM<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo de una terapia innovadora contra la distrofia miot\u00f3nica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Precipita (Crowdfunding)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2020 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>17.703 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI19\/01796<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Implicaciones experimentales y clinicas del complejo proteico rabphilin-rab\u00a0en da\u00f1o renal en la diabetes mellitus tipo 2<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Josep Red\u00f3n i Mas<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2020 &#8211; 2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>196.020 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>DTS19\/00128<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo precl\u00ednico de un f\u00e1rmaco innovador para distrofia miot\u00f3nica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2020 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>111.100 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>IAP409<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo de un modelo en Drosophila de LGMD1F<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Asociaci\u00f3n Conquistando Escalones<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>17.303 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>AFM 22346<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Development of combinatorial therapies for SMA<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>AFM Telethon<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>175000\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>FIPSE 3544-18<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Antisense RNA-therapeutics in Myotonic Dystrophy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Fundaci\u00f3n para la Innovaci\u00f3n y Prospectiva en Salud en Espa\u00f1a (FIPSE)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz, Beatriz Llamus\u00ed<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>25.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>RTI2018-094599-B-I00<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Comprensi\u00f3n de las causas moleculares de la atrofia muscular en distrofia miot\u00f3nica tipo 1<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Ministerio de Ciencia e Innovaci\u00f3n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2019 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>185.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>COST Action CA17103 COST-DARTER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>COST: European Cooperation in Science and Technology, Delivery of Antisense RNA Therapeutics (DARTER)<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>European Commission<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Virginia Arechavala<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2018 &#8211; 2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>500.000 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>HR17-00268<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>TATAMI (TherApeutic TArgeting of MIrnas) therapeutic targeting of mbnl micrornas as innovative treatments for myotonic dystrophy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Fundaci\u00f3n Bancaria La Caixa<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Rub\u00e9n Artero Allepuz<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2018 &#8211; 2021<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>997.023 \u20ac\n<\/div>\n<div style=\"margin-bottom:40px;\">\n<span style=\"color:#3D44AC; font-size:16px;\">Reference: <\/span>PI17\/00352<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Modulaci\u00f3n terap\u00e9utica de los genes MBNL como tratamientos innovadores para distrofia miot\u00f3nica<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Funding body: <\/span>Instituto de Salud Carlos III &#8211; Cofinanciado FEDER<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Principal Investigator: <\/span>Manuel P\u00e9rez Alonso, Beatriz Llamus\u00ed Tro\u00edsi<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Duration: <\/span>2018 &#8211; 2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Total budget: <\/span>75.020 \u20ac\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-13{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-13 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-13{width:100% !important;order : 0;}.fusion-builder-column-13 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-13{width:100% !important;order : 0;}.fusion-builder-column-13 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-5{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><br \/>\n<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"background-color: #e5e5e5;background-position: center center;background-repeat: no-repeat;border-width: 0px 0px 0px 0px;border-color:#e2e2e2;border-style:solid;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\">\n<div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-14 fusion_builder_column_1_1 1_1 fusion-flex-column\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\" style=\"background-position:left top;background-repeat:no-repeat;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;padding: 0px 0px 0px 0px;\">\n<div class=\"fusion-text fusion-text-17\" style=\"transform:translate3d(0,0,0);\"><h5>+ Info<\/h5>\n<\/div>\n<div class=\"fusion-tabs fusion-tabs-3 classic horizontal-tabs icon-position-left\"><style type=\"text\/css\">.fusion-tabs.fusion-tabs-3 .nav-tabs li a.tab-link{border-top-color:#f9f9fb;background-color:#f9f9fb;}.fusion-tabs.fusion-tabs-3 .nav-tabs{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{border-right-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:hover,.fusion-tabs.fusion-tabs-3 .nav-tabs li.active a.tab-link:focus{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav-tabs li a:hover{background-color:#ffffff;border-top-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .tab-pane{background-color:#ffffff;}.fusion-tabs.fusion-tabs-3 .nav,.fusion-tabs.fusion-tabs-3 .nav-tabs,.fusion-tabs.fusion-tabs-3 .tab-content .tab-pane{border-color:#e2e2e2;}<\/style><div class=\"nav\"><ul class=\"nav-tabs nav-justified\" role=\"tablist\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-fbdb646551ed3614223\" aria-selected=\"true\" id=\"fusion-tab-thesis\" href=\"#tab-fbdb646551ed3614223\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-content\"><div class=\"nav fusion-mobile-tab-nav\"><ul class=\"nav-tabs nav-justified\"><li class=\"active\"><a class=\"tab-link\" data-toggle=\"tab\" role=\"tab\" aria-controls=\"tab-fbdb646551ed3614223\" aria-selected=\"true\" id=\"mobile-fusion-tab-thesis\" href=\"#tab-fbdb646551ed3614223\"><h4 class=\"fusion-tab-heading\">THESIS<\/h4><\/a><\/li><\/ul><\/div><div class=\"tab-pane fade fusion-clearfix in active\" role=\"tabpanel\" tabindex=\"0\" aria-labelledby=\"fusion-tab-thesis\" id=\"tab-fbdb646551ed3614223\">\n<div style=\"padding-top:4%;padding-left:4%; padding-right:4%; text-align:justify;\"><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Desarrollo de modelos experimentales de LGMDD2 y rastreo de f\u00e1rmacos<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Bl\u00e1zquez Bernal, \u00c1gueda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Artero Allepuz, Ruben Dar\u00edo; Bargiela Sch\u00f6nbrunn, Ariadna<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>14\/07\/2023<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>University de Valencia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Ruta de la autofagia, MSI2 Y MIR-7 como nuevas dianas terap\u00e9uticas para la disfunci\u00f3n muscular en distrofia miot\u00f3nica de tipo 1<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Sabater Arc\u00eds, Mar\u00eda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Artero Allepuz, Rub\u00e9n; Bargiela Sch\u00f6nbrunn, Ariadna<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>01\/04\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Proof of concept of therapeutic gene modulation of MBNL1\/2 in myotonic dystrophy<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Overby, Sarah<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Artero Allepuz, Rub\u00e9n<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>21\/01\/2022<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Mejora de la actividad de un hexap\u00e9ptido anti-dm1 y an\u00e1lisis de las relaciones entre estructura y actividad de hexap\u00e9ptidos de secuencia similar<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Rapisarda, Anna Serafina Rapisarda<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Artero Allepuz, Ruben Dar\u00edo<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>31\/01\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<p><span style=\"color:#3D44AC; font-size:16px;\">Title: <\/span>Papel del complejo de prote\u00ednas rab-rabphilin en un modelo de da\u00f1o renal en drosophila<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Doctoral candidate: <\/span>Selma Soriano, Estela<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Director(s): <\/span>Artero Allepuz, Ruben Dar\u00edo<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">Date of the defense: <\/span>16\/01\/2020<br \/>\n<span style=\"color:#3D44AC; font-size:16px;\">University: <\/span>Universitat de Val\u00e8ncia<\/p>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><style type=\"text\/css\">.fusion-body .fusion-builder-column-14{width:100% !important;margin-top : 0px;margin-bottom : 20px;}.fusion-builder-column-14 > .fusion-column-wrapper {padding-top : 0px !important;padding-right : 0px !important;margin-right : 1.92%;padding-bottom : 0px !important;padding-left : 0px !important;margin-left : 1.92%;}@media only screen and (max-width:1532px) {.fusion-body .fusion-builder-column-14{width:100% !important;order : 0;}.fusion-builder-column-14 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}@media only screen and (max-width:640px) {.fusion-body .fusion-builder-column-14{width:100% !important;order : 0;}.fusion-builder-column-14 > .fusion-column-wrapper {margin-right : 1.92%;margin-left : 1.92%;}}<\/style>\n<\/div>\n<style type=\"text\/css\">.fusion-body .fusion-flex-container.fusion-builder-row-6{ padding-top : 2%;margin-top : 0px;padding-right : 0px;padding-bottom : 0px;margin-bottom : 0px;padding-left : 0px;}<\/style><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":6412,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":[],"acf":[],"_links":{"self":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7585"}],"collection":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/comments?post=7585"}],"version-history":[{"count":0,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/7585\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/pages\/6412"}],"wp:attachment":[{"href":"https:\/\/tst.incliva.es\/en\/wp-json\/wp\/v2\/media?parent=7585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}